---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075190"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:00:14.759462+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds

## Summary
- Closing on Aug 11, 2025: Helix domesticated to Delaware, merged with BBOT subsidiary; new name BridgeBio Oncology Therapeutics, ticker BBOT.
- PIPE of $260.9M (24.3M shares at $10.7173) plus $120.9M trust; $76.3M redeemed by 7.1M public shares.
- Pro forma shares: ~79.2M outstanding (excluding options); ~61.1M shares (77.2%) subject to registration rights.
- Lock-up: Helix insiders 1 year; BBOT employees below VP 6 months; other BBOT holders 1 year.
- Equity plans approved: 2025 Incentive Plan (5.37M shares + evergreen) and ESPP (0.9M shares + evergreen).

## SEC filing metadata
- accession: 0001213900-25-075190
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 9.01, 4.01, 3.03, 5.03, 8.01, 5.01, 5.02, 5.05, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea0250662-8k_bridge.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075190
- JSON: https://secwatch.observer/filing/0001213900-25-075190.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075190.txt

## Key facts
- Governance Changes
  BridgeBio Oncology Therapeutics, Inc.: Approved and adopted a new Code of Ethics in connection with closing of the Business Combination.
  - Change: code of ethics
  source text: In connection with the closing of the Business Combination, the PubCo Board approved and adopted a new Code of Ethics is applicable to all of PubCo’s employees, officers (including its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants, and will be available on PubCo’s website at https://www.bbotx.com.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
- Governance Changes
  BridgeBio Oncology Therapeutics, Inc.: Helix ceased to be a shell company upon closing of the Business Combination.
  - Change: shell status
  source text: Upon the closing of the Business Combination, Helix ceased to be a shell company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
- Governance Changes
  BridgeBio Oncology Therapeutics, Inc.: Adopted PubCo Charter effective upon filing with Delaware Secretary of State on August 11, 2025 (effective 2025-08-11).
  - Change: charter amendment
  - Effective: 2025-08-11
  source text: The PubCo Charter, which became effective upon filing with the Secretary of State of the State of Delaware on August 11, 2025, includes the amendments proposed by the Domestication Proposal, the Organizational Documents Proposal and the Advisory Organizational Documents Proposals and approved at the EGM.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
- Governance Changes
  BridgeBio Oncology Therapeutics, Inc.: Approved and adopted PubCo Bylaws effective as of the Effective Time on August 11, 2025 (effective 2025-08-11).
  - Change: bylaw amendment
  - Effective: 2025-08-11
  source text: On August 11, 2025, the PubCo Board approved and adopted the PubCo Bylaws containing the amendments proposed by the Organizational Documents Proposal and Advisory Organizational Documents Proposal and approved at the EGM, which became effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm
- M&A Transactions
  BridgeBio Oncology Therapeutics, Inc. completed an acquisition involving TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (closed 2025-08-11).
  - Action: acquisition
  - Counterparty: TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics)
  - Closing: 2025-08-11
  source text: On August 11, 2025 (the “Closing Date”), Helix Acquisition Corp. II., a Cayman Islands exempted company (“Helix”), consummated the previously announced business combination pursuant to the terms of the business combination agreement, dated February 28, 2025 and amended on June 17, 2025 (as amended, the “Business Combination Agreement”), with Helix II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DYNS (“Merger Sub”), and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation (“BBOT”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/0001213900-25-075190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.